AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14681716 — intervention group
Group type: COMPARATOR
Intervention: iso‐osmolality study with oral water intake ad libitum
Number of subjects: 10
Study 11211636 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 883
Study 11211636 — intervention group
Group type: COMPARATOR
Intervention: Usual health promotion
Number of subjects: 883
Study 9089663 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNt/A) preparation 1 injected into the left foot
Number of subjects: 0
Study 9089663 — intervention group
Group type: COMPARATOR
Intervention: Botulinum neurotoxin type A (BoNt/A) preparation 2 injected into the right foot
Number of subjects: 0
Study 9089663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations (1 and 2)
Number of subjects: 0
Study 9089663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower concentrations of toxin
Number of subjects: 0
Study 7933838 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (rhIGF-I) (100 micrograms/kg body wt subcutaneously twice daily) - short-term treatment (4 days)
Number of subjects: 9
Study 7933838 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (rhIGF-I) (100 micrograms/kg body wt subcutaneously twice daily) - long-term treatment (13-27 days)
Number of subjects: 9
Study 7933838 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 9
Study 3220789 — intervention group
Group type: EXPERIMENTAL
Intervention: Single volume exchange transfusion (ET; 80 ml/kg)
Number of subjects: 20
Study 3220789 — intervention group
Group type: COMPARATOR
Intervention: Double volume exchange transfusion (ET; 160 ml/kg)
Number of subjects: 20
Study 1985161 — intervention group
Group type: EXPERIMENTAL
Intervention: Short arm (2 additional courses; 5 weeks)
Number of subjects: 216
Study 1985161 — intervention group
Group type: COMPARATOR
Intervention: Long arm (5 additional courses with 2 additional drugs; 16 weeks)
Number of subjects: 216
Study 1985161 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (short and long)
Number of subjects: 216
Study 1985161 — intervention group
Group type: EXPERIMENTAL
Intervention: Short arm
Number of subjects: 216
Study 1985161 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 216
Study 872103 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection
Number of subjects: 0
Study 872103 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental resection
Number of subjects: 0
Study 872103 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical cystectomy with pelvic lymphadenectomy
Number of subjects: 0
Study 872103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystectomy with preoperative adjuvant radiotherapy
Number of subjects: 0
Study 872103 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiated patients
Number of subjects: 0
Study 872103 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy and/or immunotherapy
Number of subjects: 0
Study 31613945 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PDT
Number of subjects: 0
Study 31613945 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + LLLT
Number of subjects: 0
Study 31613945 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (Control)
Number of subjects: 0
Study 29065916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline starting at 50 mg daily for 1 week, increasing to 100 mg daily for up to 11 weeks (with the option of increasing to 150 mg if required)
Number of subjects: 0
Study 29065916 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 26018127 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (specific details not provided)
Number of subjects: 1104
Study 24020866 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (3.2 mg/70 kg body weight)
Number of subjects: 20
Study 24020866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20652572 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge pencil-point (PP) spinal needle
Number of subjects: 363
Study 20652572 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge Quincke (Q) spinal needle
Number of subjects: 363
Study 20652572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative time in upright sitting position (10 min or 30 min)
Number of subjects: 363
Study 19701110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed at 750 mg/m2 every 21 days with weekly cetuximab at 250 mg/m2
Number of subjects: 36
Study 19701110 — intervention group
Group type: COMPARATOR
Intervention: Historical controls of either single agent
Number of subjects: 36
Study 18000101 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant other primes (e.g., mother, roommate)
Number of subjects: 0
Study 12849651 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors with thrombolytic agents
Number of subjects: 3000
Study 12849651 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 3000
Study 12849651 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with GP IIb/IIIa inhibitors and thrombolytic agents
Number of subjects: 3000
Study 10825327 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 17
Study 10825327 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 17
Study 8992880 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral high-resistance strength training for 12 months
Number of subjects: 13
Study 8992880 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining for 8 months
Number of subjects: 13
Study 8992880 — intervention group
Group type: COMPARATOR
Intervention: Control group (Nineteen students, mean 25.7 +/- 5.2 yrs, 165 +/- 4 cm, 62.1 +/- 7.0 kg)
Number of subjects: 13
Study 1737315 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical care plus MTC services
Number of subjects: 267
Study 1737315 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 267
Study 6392170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 32%
Number of subjects: 10
Study 6392170 — intervention group
Group type: COMPARATOR
Intervention: Renografin-60
Number of subjects: 10
Study 30764549 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in Nutrition
Number of subjects: 0
Study 30764549 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in WASH/Malaria
Number of subjects: 0
Study 29050702 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fragmented QRS (fQRS) in ECG
Number of subjects: 127
Study 29050702 — intervention group
Group type: COMPARATOR
Intervention: Absence of fragmented QRS (fQRS) in ECG
Number of subjects: 127
Study 25627874 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid
Number of subjects: 409
Study 25627874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 23479062 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered advance care planning (ACP) intervention including 3- to 60-minute sessions 1 week apart, Lyon Family-Centered ACP Survey, Respecting Choices interview, and Five Wishes.
Number of subjects: 60
Study 23479062 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered advance care planning (ACP) intervention
Number of subjects: 60
Study 23479062 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus information (Control)
Number of subjects: 60
Study 21473764 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg per day)
Number of subjects: 71
Study 21473764 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclometasone (400 μg per day) with atorvastatin
Number of subjects: 71
Study 21473764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 19015209 — intervention group
Group type: EXPERIMENTAL
Intervention: Full information programme (group 1)
Number of subjects: 60
Study 19015209 — intervention group
Group type: COMPARATOR
Intervention: Full information programme (group 2)
Number of subjects: 60
Study 17110581 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders of money
Number of subjects: 9
Study 17110581 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants primed with money
Number of subjects: 9
Study 17110581 — intervention group
Group type: COMPARATOR
Intervention: Nonmoney reminders
Number of subjects: 9
Study 17110581 — intervention group
Group type: COMPARATOR
Intervention: Neutral concepts
Number of subjects: 9
Study 15373816 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10769276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate therapy
Number of subjects: 20
Study 9068936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline tablets (morning administration)
Number of subjects: 0
Study 9068936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline tablets (evening administration)
Number of subjects: 0
Study 9068936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline tablets (with food)
Number of subjects: 0
Study 9068936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline tablets (without food)
Number of subjects: 0
Study 8415147 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery in addition to standard antiemetic regimen
Number of subjects: 28
Study 8415147 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic regimen
Number of subjects: 28
Study 2951804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 16
Study 2951804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 16
Study 2951804 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (fenoterol 200 micrograms + ipratropium bromide 80 micrograms)
Number of subjects: 16
Study 2951804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31640770 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit care plus group antenatal care
Number of subjects: 671
Study 31640770 — intervention group
Group type: COMPARATOR
Intervention: Home visit care
Number of subjects: 671
Study 31640770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 671
Study 28302952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1095
Study 28302952 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1095
Study 25786565 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 1.2 mg rosuvastatin gel
Number of subjects: 65
Study 25786565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 22773192 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 98
Study 22773192 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 98
Study 21703001 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education integrated with acupuncture (two parts: self-care education in four weekly 50-minute sessions and eight weekly 50-minute acupuncture sessions)
Number of subjects: 0
Study 21703001 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 18304817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitek bone‐tendon‐bone cross pin (RIGIDfix)
Number of subjects: 40
Study 18304817 — intervention group
Group type: COMPARATOR
Intervention: Linvatec Bioscrew (control device)
Number of subjects: 40
Study 16875647 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (100 mg every 4 hours)
Number of subjects: 101
Study 12771322 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional oil (FctO)
Number of subjects: 24
Study 12771322 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OL)
Number of subjects: 24
Study 11460607 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (containing pyrophosphate, tripolyphosphate and a copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 89
Study 11460607 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice (containing tetrapotassium pyrophosphate, disodium pyrophosphate, and tetrasodium pyrophosphate in a 0.243% sodium fluoride/silica base)
Number of subjects: 89
Study 9218950 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis (11-12 weeks of gestation)
Number of subjects: 695
Study 9218950 — intervention group
Group type: COMPARATOR
Intervention: Midtrimester amniocentesis (15-16 weeks of gestation)
Number of subjects: 695
Study 8077314 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax seed ingestion
Number of subjects: 18
Study 8077314 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 18
Study 3318455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 21
Study 29934374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3851
Study 29934374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3851
Study 28251319 — intervention group
Group type: EXPERIMENTAL
Intervention: computer dynamic posturography (CDP) training
Number of subjects: 139
Study 28251319 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 139
Study 25667122 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.9 mg kg(‐1))
Number of subjects: 80
Study 23547488 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest PRO‐HEALTH Rinse (CPH)
Number of subjects: 171
Study 23547488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cēpacol (C)
Number of subjects: 171
Study 23547488 — intervention group
Group type: EXPERIMENTAL
Intervention: Scope (S)
Number of subjects: 171
Study 23547488 — intervention group
Group type: EXPERIMENTAL
Intervention: Viadent ADVANCED CARE (V)
Number of subjects: 171
Study 23547488 — intervention group
Group type: COMPARATOR
Intervention: Brushing alone (BA)
Number of subjects: 171
Study 21908961 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA) with 3 ml of 0.75% ropivacaine
Number of subjects: 50
Study 21908961 — intervention group
Group type: COMPARATOR
Intervention: Combined sciatic/lumbar plexus nerve block (CSLPB) with 10 ml 0.75% ropivacaine and 10 ml of normal saline (20 ml total)
Number of subjects: 50
Study 17507641 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional body weight‐supported treadmill training for 4 weeks
Number of subjects: 14
Study 17507641 — intervention group
Group type: COMPARATOR
Intervention: General physical therapy
Number of subjects: 14
Study 17507641 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional body weight‐supported treadmill training
Number of subjects: 14
Study 17507641 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional gait training
Number of subjects: 14
Study 17157760 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice Group
Number of subjects: 864
Study 17157760 — intervention group
Group type: COMPARATOR
Intervention: Community Group
Number of subjects: 864
Study 17157760 — intervention group
Group type: COMPARATOR
Intervention: Pain prevalence method
Number of subjects: 864
Study 17157760 — intervention group
Group type: COMPARATOR
Intervention: Pain Management Index (PMI)
Number of subjects: 864
Study 14622081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 60
Study 14622081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus self-exposure (FLU + SE)
Number of subjects: 60
Study 14622081 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus self-exposure (PLA + SE)
Number of subjects: 60
Study 11060940 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending to pain-related thoughts
Number of subjects: 39
Study 11060940 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressing pain-related thoughts
Number of subjects: 39
Study 11060940 — intervention group
Group type: COMPARATOR
Intervention: Control (thinking about anything)
Number of subjects: 39
Study 7588456 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 35
Study 7588456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7588456 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving long-term anticonvulsant therapy
Number of subjects: 35
Study 2121394 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (buserelin) 100 micrograms
Number of subjects: 14
Study 2121394 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG 50 IU/kg
Number of subjects: 14
Study 2121394 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 14
Study 582772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg WE 941
Number of subjects: 10
Study 582772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg WE 941
Number of subjects: 10
Study 582772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg WE 941
Number of subjects: 10
Study 582772 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg flurazepam
Number of subjects: 10
Study 582772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31621850 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear models with variable selection
Number of subjects: 0
Study 31621850 — intervention group
Group type: COMPARATOR
Intervention: Models developed from one country and validated in another
Number of subjects: 0
Study 31621850 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical models applied to Year‐3 data
Number of subjects: 0
Study 31093942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention programme (CATI)
Number of subjects: 0
Study 27810347 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Mechanical Circulatory Support (pMCS)
Number of subjects: 48
Study 27810347 — intervention group
Group type: COMPARATOR
Intervention: Intra-Aortic Balloon Pump (IABP)
Number of subjects: 48
Study 24460003 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted breast cancer screening educational intervention (n = 147)
Number of subjects: 300
Study 24460003 — intervention group
Group type: COMPARATOR
Intervention: Mammography screening brochure published by the National Cancer Institute (n = 153)
Number of subjects: 300
Study 23299013 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV-6/11/16/18 vaccine
Number of subjects: 700
Study 23299013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 23299013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 700
Study 21689206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational technique
Number of subjects: 78
Study 21689206 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 78
Study 18685531 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically stimulated eccentric exercise (STIM)
Number of subjects: 16
Study 18685531 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary eccentric exercise (VOL)
Number of subjects: 16
Study 16515419 — intervention group
Group type: EXPERIMENTAL
Intervention: Urge incontinence
Number of subjects: 782
Study 16515419 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal daytime sleepiness
Number of subjects: 782
Study 12721239 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training on cycle ergometers three times per week for 15 weeks
Number of subjects: 53
Study 12721239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 53
Study 11525594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh broccoli (200 g)
Number of subjects: 12
Study 11525594 — intervention group
Group type: COMPARATOR
Intervention: Steamed broccoli (200 g)
Number of subjects: 12
Study 9422300 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 36
Study 9422300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8288160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (15 mg twice daily for 8 days)
Number of subjects: 18
Study 8288160 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 obese patients)
Number of subjects: 18
Study 3550084 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 53
Study 3550084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 29536609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated Axxess bifurcation stent and Biomatrix stents
Number of subjects: 40
Study 29536609 — intervention group
Group type: COMPARATOR
Intervention: Culotte stenting using Xience stents
Number of subjects: 40
Study 27863277 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/d for 28 days)
Number of subjects: 13
Study 27863277 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) with Vitamin D
Number of subjects: 13
Study 27863277 — intervention group
Group type: COMPARATOR
Intervention: Placebo during Resistance training (RT)
Number of subjects: 13
Study 27863277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AB) with Vitamin D
Number of subjects: 13
Study 24332524 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (10 g/d)
Number of subjects: 52
Study 24332524 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (10 g/d)
Number of subjects: 52
Study 21877913 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin monotherapy (n=27)
Number of subjects: 59
Study 21877913 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII) (n=32)
Number of subjects: 59
Study 21877913 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 59
Study 19164492 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release bupropion (150-300 mg once daily)
Number of subjects: 0
Study 19164492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18315510 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response training (stress management)
Number of subjects: 122
Study 18315510 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (control)
Number of subjects: 122
Study 16389916 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug
Number of subjects: 0